Press Room

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.

HELENA, Montana – Residents from across the state will rally at noon on Wednesday at the Capitol Flag Plaza to send a clear and urgent message to lawmakers: It is time to remove the sunset clause from Montana Medicaid expansion.

COLUMBIA, S.C. – As the 2025 legislative session begins Tuesday, the American Cancer Society Cancer Action Network (ACS CAN) urges lawmakers to support policies that will reduce the cancer burden in the Palmetto State.

As the 2025 legislative session gets underway, the American Cancer Society Cancer Action Network (ACS CAN) urges legislators to prioritize improving access to cancer care and increasing funding for tobacco control programs to ease the burden of cancer in Michigan. 

HELENA, Mont. – Tens of thousands of Montanans are counting on lawmakers to protect their access to health care as business convenes this week in the state capitol.
 

Two years after Ocean City local Jeanmarie Mason’s breast cancer returned and spread to her bones, her daughter Julie Groob also experienced a recurrence of her cervical cancer, bringing the two closer together than ever and uniting them in the fight against cancer. As volunteers with the American Cancer Society Cancer Action Network (ACS CAN), Jeanmarie and Julie were among key voices in securing a medical debt relief victory in 2024. The pair are approaching the legislative session in 2025 eager to share their stories and advance critical proposals to limit the burden of disease across the cancer continuum.

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Maryland Government Relations Director Lance Kilpatrick:

“In 2024, Maryland state lawmakers heard from advocates across the disease spectrum and from every corner of the state, who united together to send a resounding message: improve access to lifesaving medication. Though the legislature did not advance the proposal to prohibit the use of copay accumulator adjustment programs, advocates are hopeful that lawmakers won’t miss the same opportunity in 2025.

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) New York City Senior Government Relations Director Michael Davoli:

“Late last year, Mayor Adams laid out a goal of reducing deaths from cancers that can be detected early through routine screening by 20% by 2030. His HealthyNYC initiative might be viewed as overly ambitious but we at ACS CAN believe it is possible to achieve, should city leaders look in the right direction. Patient navigation is that right direction. It is one of the most promising solutions towards achieving this goal, and cancer survivors throughout the city are eager to see it actualized by the Adams administration through an improvement in New Yorkers’ access to patient navigation.

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Pennsylvania Government Relations Director Donna Greco:

“In 2024, ACS CAN was proud to see the Pennsylvania Legislature mobilize swiftly and in a bipartisan manner to bring the promise of precision medicine to more patients. Beginning in the new year, Act 39 of 2024 will make it so that all patients who can benefit and are insured through a state-regulated health plan will receive coverage for biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments. Pennsylvanians also secured a victory for access to care through Act 42 of 2024, the newly enacted legislation that includes telemedicine as a covered benefit in the Commonwealth.